Volumes : Issues : Articles

Cancer Watch 2000
Cancer Watch 2001
Cancer Watch 2002
Cancer Watch 2003
Cancer Watch 2004
Cancer Watch 2005
Cancer Watch 2006
Cancer Watch 2007
Cancer Watch 2008
Cancer Watch 2009
Cancer Watch 2010
Cancer Watch 2011
Cancer Watch 2012

CW October 2004

Volume 13
Issue Number 10
October 2004
ISSN 10593802

Targeted Therapies for Cancer

Phase II trial for Velcade, a proteasome inhibitor, in patients with relapsed or refractory mantle cell lymphoma is launched worldwide.
Go to Previous Page
Go to Next Page

Source & Additional Reading

Prospective participants can call 1-866-VELCADE (835-2233) for more information about eligibility or to find a study site in their area.

Purchase Downloadable Full-text PDF of Article: $10.00

Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details.

Download Complete Issue CW October 2004

Purchase Downloadable Full-text PDF of Complete Issue: $20.00

<< Go Back to CW October 2004